UCSF home page UCSF home page About UCSF UCSF Medical Center
UCSF navigation bar
UCSF Cardiology
Transforming medicine through innovation and collaboration.
Department of Medicine

Faculty Profiles

David Waters, MD
M_MED-ZSFG-CARD
Professor

SFGH NH
415-206-8320
David.Waters@ucsf.edu

Recent Articles (145)

Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, Barter P, Waters DD, Ray KK. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the Treating to New Targets (TNT) Trial. Circulation. 2018 Apr 04.

Waters DD, Vogt L. Lipids, inflammation, and chronic kidney disease: a SHARP perspective. Kidney Int. 2018 Apr; 93(4):784-786.

Ong KL, Waters DD, Fayyad R, Vogt L, Melamed S, DeMicco DA, Rye KA, Barter PJ. Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin. J Am Heart Assoc. 2018 Jan 22; 7(2).

Waters DD, Bangalore S, Fayyad R, DeMicco DA, Laskey R, Melamed S, Barter PJ. Visit-to-visit variability of lipid measurements as predictors of cardiovascular events. J Clin Lipidol. 2018 Mar - Apr; 12(2):356-366.

Waters DD. Are Cholesterol Treatment Targets a Deterrent to Optimal Lipid-Lowering Therapy? JAMA Cardiol. 2017 Dec 01; 2(12):1392-1393.

Hsue PY, Waters DD. Heart failure in persons living with HIV infection. Curr Opin HIV AIDS. 2017 Nov; 12(6):534-539.

Arsenault BJ, Petrides F, Tabet F, Bao W, Hovingh GK, Boekholdt SM, Ramin-Mangata S, Meilhac O, DeMicco D, Rye KA, Waters DD, Kastelein JJP, Barter P, Lambert G. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. J Clin Lipidol. 2018 Jan - Feb; 12(1):130-136.

Waters DD, Nattel S. Taking Hockey to Heart: Potential Coronary Risks of Watching Exciting Games. Can J Cardiol. 2017 Dec; 33(12):1517-1519.

Rosenson RS, Larrey D, Waters DD, Olsson AG. RE: Praluent (Alirocumab)-Induced Renal Injury. J Pharm Pract. 2018 Apr; 31(2):138-139.

Waters DD, Bangalore S. The Evolution of Myocardial Infarction: When the Truths We Hold To Be Self-Evident No Longer Have Evidence. Can J Cardiol. 2017 10; 33(10):1209-1211.

Bangalore S, Messerli FH, Waters DD. Body-Weight Fluctuations and Outcomes in Coronary Disease. N Engl J Med. 2017 07 06; 377(1):95-6.

Waters DD, Hsue PY. PCSK9 Inhibition to Reduce Cardiovascular Risk: Tempering Expectations. Circ Res. 2017 May 12; 120(10):1537-1539.

Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Body-Weight Fluctuations and Outcomes in Coronary Disease. N Engl J Med. 2017 04 06; 376(14):1332-1340.

Waters DD. The Rise and Fall of Tuberculosis and Atherosclerosis: First There Is a Mountain…. Can J Cardiol. 2017 03; 33(3):295-297.

Bangalore S, Fayyad R, Messerli FH, Laskey R, DeMicco DA, Kastelein JJ, Waters DD. Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial. Am J Cardiol. 2017 Feb 01; 119(3):379-387.

Waters DD, Boekholdt SM. An Evidence-Based Guide to Cholesterol-Lowering Guidelines. Can J Cardiol. 2017 Mar; 33(3):343-349.

Kohli P, Knowles JW, Sarraju A, Waters DD, Reaven G. Metabolic Markers to Predict Incident Diabetes Mellitus in Statin-Treated Patients (from the Treating to New Targets and the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trials). Am J Cardiol. 2016 Nov 01; 118(9):1275-1281.

Yan P, Tan EK, Choo JC, Liew CF, Lau T, Waters DD. Statin-centric versus low-density lipoprotein-centric approach for atherosclerotic cardiovascular disease prevention: a Singapore perspective. Singapore Med J. 2016 Jul; 57(7):360-7.

Azar RR, Kadri Z, Waters DD. Performance Deficiencies in the Treatment of ST-Elevation Myocardial Infarction in Québec: "Tis But a Part We See, and Not a Whole". Can J Cardiol. 2016 11; 32(11):1294.e5-1294.e7.

Arsenault BJ, Kohli P, Lambert G, DeMicco DA, Laskey R, Messig MM, Kastelein JJ, Waters DD. Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study). Am J Cardiol. 2016 Aug 15; 118(4):494-8.

Waters DD, Hsue PY, Bangalore S. PCSK9 Inhibitors for Statin Intolerance? JAMA. 2016 Apr 19; 315(15):1571-2.

Waters DD, Arsenault BJ. Predicting Prognosis in Acute Coronary Syndromes: Makeover Time for TIMI and GRACE? Can J Cardiol. 2016 11; 32(11):1290-1293.

Bangalore S, Fayyad R, Kastelein JJ, Laskey R, Amarenco P, DeMicco DA, Waters DD. 2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis? Am J Med. 2016 Apr; 129(4):384-91.

Waters DD, Chau KH. Tribulations of Recent Cardiology Trials, the Audacity of Hope, and HOPE-3. Can J Cardiol. 2016 Mar; 32(3):275-7.

Setia S, Fung SS, Waters DD. Doctors' knowledge, attitudes, and compliance with 2013 ACC/AHA guidelines for prevention of atherosclerotic cardiovascular disease in Singapore. Vasc Health Risk Manag. 2015; 11:303-10.

Waters DD. LDL-cholesterol lowering and renal outcomes. Curr Opin Lipidol. 2015 Jun; 26(3):195-9.

Waters DD, Hsue PY. PCSK9 Inhibition to Lower LDL-Cholesterol and Reduce Cardiovascular Risk: Great Expectations. Circ Res. 2015 May 08; 116(10):1643-5.

Preiss D, Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, Rahimi K, Colhoun HM, Waters DD, LaRosa JC, Amarenco P, Pedersen TR, Tikkanen MJ, Koren MJ, Poulter NR, Sever PS, Ridker PM, MacFadyen JG, Solomon SD, Davis BR, Simpson LM, Nakamura H, Mizuno K, Marfisi RM, Marchioli R, Tognoni G, Athyros VG, Ray KK, Gotto AM, Clearfield MB, Downs JR, McMurray JJ. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J. 2015 Jun 21; 36(24):1536-46.

Kohli P, Waters DD, Nemr R, Arsenault BJ, Messig M, DeMicco DA, Laskey R, Kastelein JJP. Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL. J Am Coll Cardiol. 2015 Feb 03; 65(4):402-404.

Banerjee A, Waters D, Camacho OM, Minet E. Quantification of plasma microRNAs in a group of healthy smokers, ex-smokers and non-smokers and correlation to biomarkers of tobacco exposure. Biomarkers. 2015 Mar; 20(2):123-31.

Boekholdt SM, Hovingh GK, Waters DD, Grundy SM, Kastelein JJP. Reply: statin-induced low low-density lipoprotein cholesterol level: is lower better? J Am Coll Cardiol. 2015 Jan 06; 65(1):109.

Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ. Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. PLoS One. 2014; 9(12):e114519.

Hsue PY, Bittner VA, Betteridge J, Fayyad R, Laskey R, Wenger NK, Waters DD. Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials. Am J Cardiol. 2015 Feb 15; 115(4):447-53.

Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, Sofat R, Stender S, Johnson PC, Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li K, Palmen J, Howard P, Cooper JA, Drenos F, Li YR, Lowe G, Gallacher J, Stewart MC, Tzoulaki I, Buxbaum SG, van der A DL, Forouhi NG, Onland-Moret NC, van der Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, Baceviciene M, Tamosiunas A, Pajak A, Topor-Madry R, Stepaniak U, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, de Faire U, Veglia F, Ford I, Jukema JW, Westendorp RG, de Borst GJ, de Jong PA, Algra A, Spiering W, Maitland-van der Zee AH, Klungel OH, de Boer A, Doevendans PA, Eaton CB, Robinson JG, Duggan D. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015 Jan 24; 385(9965):351-61.

Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM, Ridker PM, Grundy SM, Kastelein JJ. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014 Aug 05; 64(5):485-94.

Waters DD. The past and future of heart institutes: having moved beyond the one-trick pony. Can J Cardiol. 2014 Dec; 30(12 Suppl):S478-82.

Kohli P, Waters DD. Looking for coronary disease in patients with atrial fibrillation. Can J Cardiol. 2014 Aug; 30(8):861-3.

Tardif JC, Ballantyne CM, Barter P, Dasseux JL, Fayad ZA, Guertin MC, Kastelein JJ, Keyserling C, Klepp H, Koenig W, L'Allier PL, Lespérance J, Lüscher TF, Paolini JF, Tawakol A, Waters DD. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J. 2014 Dec 07; 35(46):3277-86.

Bangalore S, Fayyad R, Hovingh GK, Laskey R, Vogt L, DeMicco DA, Waters DD. Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials. Am J Cardiol. 2014 Jun 15; 113(12):2018-20.

Ong KL, Waters DD, Messig M, DeMicco DA, Rye KA, Barter PJ. Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study). Am J Cardiol. 2014 May 15; 113(10):1593-8.

Waters DD, Azar RR. The curse of target lesion calcification: still active after all these years. J Am Coll Cardiol. 2014 May 13; 63(18):1855-6.

Arsenault BJ, Boekholdt SM, Mora S, DeMicco DA, Bao W, Tardif JC, Amarenco P, Pedersen T, Barter P, Waters DD. Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). Am J Cardiol. 2014 Apr 15; 113(8):1378-82.

Ong KL, Barter PJ, Waters DD. Cardiovascular drugs that increase the risk of new-onset diabetes. Am Heart J. 2014 Apr; 167(4):421-8.

Waters DD. Meta-analyses of statin trials: clear benefit for primary prevention in the elderly. J Am Coll Cardiol. 2013 Dec 03; 62(22):2100-1.

Waters DD, Boekholdt SM, Pedersen TR. Reply: To PMID 23219296. J Am Coll Cardiol. 2013 May 07; 61(18):1934.

Waters DD, Ho JE, Boekholdt SM, DeMicco DA, Kastelein JJ, Messig M, Breazna A, Pedersen TR. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol. 2013 Jan 15; 61(2):148-52.

Waters DD. Papering over the cracks: meta-analysis to define the role of percutaneous coronary intervention in patients with stable angina. Can J Cardiol. 2013 Apr; 29(4):411-4.

Bittner V, Wenger NK, Waters DD, DeMicco DA, Messig M, LaRosa JC. Vitamin D levels do not predict cardiovascular events in statin-treated patients with stable coronary disease. Am Heart J. 2012 Sep; 164(3):387-93.

Santos RD, Waters DD, Tarasenko L, Messig M, Jukema JW, Chiang CW, Ferrieres J, Foody JM. A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the Lipid Treatment Assessment Project 2. Atherosclerosis. 2012 Sep; 224(1):150-3.

Waters DD. Utility of biomarkers and imaging in the development of drugs for the treatment of coronary atherosclerosis. Can J Cardiol. 2012 Nov-Dec; 28(6):687-92.

Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, Deedwania P, Kastelein JJ, Waters DD. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation. 2012 Apr 24; 125(16):1979-87.

Ho JE, Waters DD, Kean A, Wilson DJ, Demicco DA, Breazna A, Wun CC, Deedwania PC, Khush KK. Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study). Am J Cardiol. 2012 Jun 15; 109(12):1761-6.

Rodriguez F, Santos RD, Messig M, Tarasenko L, Ferrières J, Jukema JW, Chiang CW, Waters DD, Foody JM. Comparison of lipid profiles and attainment of lipid goals in patients <65 years versus patients =65 years (from the Lipid Treatment Assessment Project [L-TAP] 2). Am J Cardiol. 2012 Jun 15; 109(12):1738-42.

Nicholls SJ, Cavender MA, Kastelein JJ, Schwartz G, Waters DD, Rosenson RS, Bash D, Hislop C. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovasc Drugs Ther. 2012 Feb; 26(1):71-5.

Hsue PY, Ordovas K, Lee T, Reddy G, Gotway M, Schnell A, Ho JE, Selby V, Madden E, Martin JN, Deeks SG, Ganz P, Waters DD. Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium. Am J Cardiol. 2012 Mar 01; 109(5):742-7.

Arsenault BJ, Boekholdt SM, Hovingh GK, Hyde CL, DeMicco DA, Chatterjee A, Barter P, Deedwania P, Waters DD, LaRosa JC, Pedersen TR, Kastelein JJ. The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. Circ Cardiovasc Genet. 2012 Feb 01; 5(1):51-7.

Frey P, Waters DD. Tobacco smoke and cardiovascular risk: a call for continued efforts to reduce exposure. Curr Opin Cardiol. 2011 Sep; 26(5):424-8.

Secemsky E, Lange D, Waters DD, Goldschlager NF, Hsue PY. Hemodynamic and arrhythmogenic effects of cocaine in hypertensive individuals. J Clin Hypertens (Greenwich). 2011 Oct; 13(10):744-9.

Barter PJ, Rye KA, Tardif JC, Waters DD, Boekholdt SM, Breazna A, Kastelein JJ. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation. 2011 Aug 02; 124(5):555-62.

Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011 Jun 22; 305(24):2556-64.

Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun CC, Kastelein JJ, Colhoun H, Barter P. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011 Apr 05; 57(14):1535-45.

Chiang CW, Santos RD, Waters DD, Messig M, Tarasenko L, Jukema JW, Ferrières J, Foody J, Seung KB. Reaching C-reactive protein and low-density lipoprotein cholesterol goals in dyslipidemic patients (from the Lipid Treatment Assessment Project [L-TAP] 2). Am J Cardiol. 2011 Jun 01; 107(11):1639-43.

Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. J Am Coll Cardiol. 2011 Jan 04; 57(1):63-9.

Frey P, Waters DD, DeMicco DA, Breazna A, Samuels L, Pipe A, Wun CC, Benowitz NL. Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] trials). Am J Cardiol. 2011 Jan 15; 107(2):145-50.

Frey P, Waters DD. Statins before stents: does an ounce of prevention improve outcomes? Can J Cardiol. 2010 Nov; 26(9):486-7.

Jukema JW, Chiang CW, Ferrières J, Santos RD, Verdejo J, Waters DD, Messig M, Tarasenko L. Lipid goals among patients with diabetes or metabolic syndrome: Lipid Treatment Assessment Project (L-TAP) 2. Curr Med Res Opin. 2010 Nov; 26(11):2589-97.

Rosenson RS, Hislop C, Elliott M, Stasiv Y, Goulder M, Waters D. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J Am Coll Cardiol. 2010 Sep 28; 56(14):1079-88.

van den Bogaard B, van den Born BJ, Fayyad R, Waters DD, DeMicco DA, LaRosa JC, Kastelein JJ, Holme I. On-treatment lipoprotein components and risk of cerebrovascular events in the Treating to New Targets study. Eur J Clin Invest. 2011 Feb; 41(2):134-42.

Ho JE, Bittner V, Demicco DA, Breazna A, Deedwania PC, Waters DD. Usefulness of heart rate at rest as a predictor of mortality, hospitalization for heart failure, myocardial infarction, and stroke in patients with stable coronary heart disease (Data from the Treating to New Targets [TNT] trial). Am J Cardiol. 2010 Apr 01; 105(7):905-11.

Waters DD. Exploring new indications for statins beyond atherosclerosis: Successes and setbacks. J Cardiol. 2010 Mar; 55(2):155-62.

Rosen VM, Taylor DC, Parekh H, Pandya A, Thompson D, Kuznik A, Waters DD, Drummond M, Weinstein MC. Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US. Pharmacoeconomics. 2010; 28(1):47-60.

Santos RD, Waters DD, Tarasenko L, Messig M, Jukema JW, Ferrières J, Verdejo J, Chiang CW. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2. Am Heart J. 2009 Nov; 158(5):860-6.

Waters DD, Ku I. Early statin therapy in acute coronary syndromes: the successful cycle of evidence, guidelines, and implementation. J Am Coll Cardiol. 2009 Oct 06; 54(15):1434-7.

Heinonen T, Waters DD, Libby P, Tardif JC. A winter's tale: report from the First Annual Canadian Biomarkers and Surrogate Endpoints Symposium. Can J Cardiol. 2009 Sep; 25(9):527-32.

Faergeman O, Holme I, Fayyad R, Bhatia S, Grundy SM, Kastelein JJ, LaRosa JC, Larsen ML, Lindahl C, Olsson AG, Tikkanen MJ, Waters DD, Pedersen TR. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol. 2009 Aug 15; 104(4):459-63.

Waters DD, Brotons C, Chiang CW, Ferrières J, Foody J, Jukema JW, Santos RD, Verdejo J, Messig M, McPherson R, Seung KB, Tarasenko L. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009 Jul 07; 120(1):28-34.

Waters DD. Clinical insights from the Treating to New Targets trial. Prog Cardiovasc Dis. 2009 May-Jun; 51(6):487-502.

Mutungi G, Waters D, Ratliff J, Puglisi M, Clark RM, Volek JS, Fernandez ML. Eggs distinctly modulate plasma carotenoid and lipoprotein subclasses in adult men following a carbohydrate-restricted diet. J Nutr Biochem. 2010 Apr; 21(4):261-7.

Rosenson RS, Hislop C, McConnell D, Elliott M, Stasiv Y, Wang N, Waters DD. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet. 2009 Feb 21; 373(9664):649-58.

Wohl DA, Waters D, Simpson RJ, Richard S, Schnell A, Napravnik S, Keys J, Eron JJ, Hsue P. Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis. 2008 Oct 15; 47(8):1105-8.

Johnson C, Waters DD, DeMicco DA, Breazna A, Bittner V, Greten H, Grundy SM, LaRosa JC. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). Am J Cardiol. 2008 Nov 15; 102(10):1312-7.

Shah SJ, Waters DD, Barter P, Kastelein JJ, Shepherd J, Wenger NK, DeMicco DA, Breazna A, LaRosa JC. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol. 2008 May 20; 51(20):1938-43.

Krauss RM, Mangravite LM, Smith JD, Medina MW, Wang D, Guo X, Rieder MJ, Simon JA, Hulley SB, Waters D, Saad M, Williams PT, Taylor KD, Yang H, Nickerson DA, Rotter JI. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation. 2008 Mar 25; 117(12):1537-44.

Jones RW, Kivipelto M, Feldman H, Sparks L, Doody R, Waters DD, Hey-Hadavi J, Breazna A, Schindler RJ, Ramos H. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimers Dement. 2008 Mar; 4(2):145-53.

Vora AN, Ouyang P, Bittner V, Tardif JC, Waters DD, Vaidya D. Racial differences of lipoprotein subclass distributions in postmenopausal women. Ethn Dis. 2008; 18(2):176-80.

DeFaria Yeh D, Waters DD. Preventing and treating stroke and transient ischemic attack. Am J Cardiol. 2008 Jan 15; 101(2):270-3.

Kinlay S, Schwartz GG, Olsson AG, Rifai N, Szarek M, Waters DD, Libby P, Ganz P. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arterioscler Thromb Vasc Biol. 2008 Jan; 28(1):142-7.

Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007 Nov 22; 357(21):2109-22.

Moran A, Simon JA, Shiboski S, Pickering TG, Waters D, Rotter JI, Lyon C, Nickerson D, Yang H, Saad M, Hsueh W, Krauss RM. Differential effects of ramipril on ambulatory blood pressure in African Americans and Caucasians. Am J Hypertens. 2007 Aug; 20(8):884-91.

Waters D, Clark RM, Greene CM, Contois JH, Fernandez ML. Change in plasma lutein after egg consumption is positively associated with plasma cholesterol and lipoprotein size but negatively correlated with body size in postmenopausal women. J Nutr. 2007 Apr; 137(4):959-63.

Yeboah J, Reboussin DM, Waters D, Kowalchuk G, Herrington DM. Effects of estrogen replacement with and without medroxyprogesterone acetate on brachial flow-mediated vasodilator responses in postmenopausal women with coronary artery disease. Am Heart J. 2007 Mar; 153(3):439-44.

Hsue PY, McManus D, Selby V, Ren X, Pillutla P, Younes N, Goldschlager N, Waters DD. Cardiac arrest in patients who smoke crack cocaine. Am J Cardiol. 2007 Mar 15; 99(6):822-4.

Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJ, Lewis SJ, Wenger NK. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation. 2007 Feb 06; 115(5):576-83.

DeFaria Yeh D, Waters DD. The SPARCL study: extending the indications of statin therapy for stroke? Nat Clin Pract Cardiovasc Med. 2007 Mar; 4(3):128-9.

Marcus GM, Cohen J, Varosy PD, Vessey J, Rose E, Massie BM, Chatterjee K, Waters D. The utility of gestures in patients with chest discomfort. Am J Med. 2007 Jan; 120(1):83-9.

Hsue PY, Hunt PW, Sinclair E, Bredt B, Franklin A, Killian M, Hoh R, Martin JN, McCune JM, Waters DD, Deeks SG. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS. 2006 Nov 28; 20(18):2275-83.

Friedewald VE, McPherson R, Roberts R, Roberts WC, Waters DD. Statin therapy in acute coronary syndrome. Am J Cardiol. 2007 Jan 15; 99(2):213-21.

Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM, Carter R, Breazna A, Kastelein JJ, Grundy SM. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol. 2006 Nov 07; 48(9):1793-9.

Khush KK, Waters DD. Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials. J Card Fail. 2006 Oct; 12(8):664-74.

Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006 Sep 09; 368(9539):919-28.

Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006 Jun; 29(6):1220-6.

Waters DD. What the statin trials have taught us. Am J Cardiol. 2006 Jul 01; 98(1):129-34.

Herron KL, McGrane MM, Waters D, Lofgren IE, Clark RM, Ordovas JM, Fernandez ML. The ABCG5 polymorphism contributes to individual responses to dietary cholesterol and carotenoids in eggs. J Nutr. 2006 May; 136(5):1161-5.

Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, Schoenhagen P, Waters DD, Pepine CJ, Crowe TD, Davidson MH, Deanfield JE, Wisniewski LM, Hanyok JJ, Kassalow LM. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006 Mar 23; 354(12):1253-63.

Clark RM, Herron KL, Waters D, Fernandez ML. Hypo- and hyperresponse to egg cholesterol predicts plasma lutein and beta-carotene concentrations in men and women. J Nutr. 2006 Mar; 136(3):601-7.

Simon JA, Lin F, Hulley SB, Blanche PJ, Waters D, Shiboski S, Rotter JI, Nickerson DA, Yang H, Saad M, Krauss RM. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am J Cardiol. 2006 Mar 15; 97(6):843-50.

Greene CM, Waters D, Clark RM, Contois JH, Fernandez ML. Plasma LDL and HDL characteristics and carotenoid content are positively influenced by egg consumption in an elderly population. Nutr Metab (Lond). 2006 Jan 06; 3:6.

Hsue PY, Waters DD. What a cardiologist needs to know about patients with human immunodeficiency virus infection. Circulation. 2005 Dec 20; 112(25):3947-57.

Khush KK, Rapaport E, Waters D. The history of the coronary care unit. Can J Cardiol. 2005 Oct; 21(12):1041-5.

Waters DD. Safety of high-dose atorvastatin therapy. Am J Cardiol. 2005 Sep 05; 96(5A):69F-75F.

McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, Simon J, Krauss RM. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol. 2005 Aug 01; 96(3):399-404.

Ruo B, Tripputi MT, Hsue PY, Saigo M, Ouyang P, Waters DD. Usefulness of serum endothelin levels in predicting death and myocardial infarction but not coronary progression in postmenopausal women with coronary disease (from the Women's Angiographic Vitamin and Estrogen [WAVE] study). Am J Cardiol. 2005 Aug 01; 96(3):335-8.

Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J. 2005 May; 26(9):890-6.

LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005 Apr 07; 352(14):1425-35.

Liu C, Waters DD. Chlamydia pneumoniae and atherosclerosis: from Koch postulates to clinical trials. Prog Cardiovasc Dis. 2005 Jan-Feb; 47(4):230-9.

Kelemen M, Vaidya D, Waters DD, Howard BV, Cobb F, Younes N, Tripputti M, Ouyang P. Hormone therapy and antioxidant vitamins do not improve endothelial vasodilator function in postmenopausal women with established coronary artery disease: a substudy of the Women's Angiographic Vitamin and Estrogen (WAVE) trial. Atherosclerosis. 2005 Mar; 179(1):193-200.

Saigo M, Waters DD, Abe S, Biro S, Minagoe S, Maruyama I, Tei C. Soluble fibrin, C-reactive protein, fibrinogen, factor VII, antithrombin, proteins C and S, tissue factor, D-dimer, and prothrombin fragment 1 + 2 in men with acute myocardial infarction

Nair GV, Waters D, Rogers W, Kowalchuk GJ, Stuckey TD, Herrington DM. Pulse pressure and coronary atherosclerosis progression in postmenopausal women. Hypertension. 2005 Jan; 45(1):53-7.

Khush KK, Waters D. Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients. Cleve Clin J Med. 2004 Aug; 71(8):609-16.

Howard BV, Hsia J, Ouyang P, Van Voorhees L, Lindsay J, Silverman A, Alderman EL, Tripputi M, Waters DD. Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance. Circulation. 2004 Jul 13; 110(2):201-6.

Saigo M, Hsue PY, Waters DD. Role of thrombotic and fibrinolytic factors in acute coronary syndromes. Prog Cardiovasc Dis. 2004 May-Jun; 46(6):524-38.

Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, Waters DD. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004 Apr 06; 109(13):1603-8.

Waters DD, Gordon D, Rossouw JE, Cannon RO, Collins P, Herrington DM, Hsia J, Langer R, Mosca L, Ouyang P, Sopko G, Stefanick ML. Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002 : Section 4: lessons from hormone replacement trials. Circulation. 2004 Feb 17; 109(6):e53-5.

Bairey Merz N, Bonow RO, Sopko G, Balaban RS, Cannon RO, Gordon D, Hand MM, Hayes SN, Lewis JF, Long T, Manolio TA, Maseri A, Nabel EG, Desvigne Nickens P, Pepine CJ, Redberg RF, Rossouw JE, Selker HP, Shaw LJ, Waters DD. Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002: executive summary. Circulation. 2004 Feb 17; 109(6):805-7.

Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol. 2004 Jan 15; 93(2):154-8.

Hsue PY, Giri K, Erickson S, MacGregor JS, Younes N, Shergill A, Waters DD. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation. 2004 Jan 27; 109(3):316-9.

Schwartz GG, Ganz P, Waters D, Arikian S. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. Am J Cardiol. 2003 Nov 01; 92(9):1109-12.

Waters D. Statins and safety: applying the results of randomized trials to clinical practice. Am J Cardiol. 2003 Sep 15; 92(6):692-5.

Jha AK, Varosy PD, Kanaya AM, Hunninghake DB, Hlatky MA, Waters DD, Furberg CD, Shlipak MG. Differences in medical care and disease outcomes among black and white women with heart disease. Circulation. 2003 Sep 02; 108(9):1089-94.

Metz L, Waters DD. Implications of cigarette smoking for the management of patients with acute coronary syndromes. Prog Cardiovasc Dis. 2003 Jul-Aug; 46(1):1-9.

Fram DB, Azar RR, Ahlberg AW, Gillam LD, Mitchel JF, Kiernan FJ, Hirst JA, Mather JF, Ficaro E, Cyr G, Waters D, Heller GV. Duration of abnormal SPECT myocardial perfusion imaging following resolution of acute ischemia: an angioplasty model. J Am Coll Cardiol. 2003 Feb 05; 41(3):452-9.

Mostaghel E, Waters D. Women do benefit from lipid lowering: latest clinical trial data. Cardiol Rev. 2003 Jan-Feb; 11(1):4-12.

Hong H, Aksenov S, Guan X, Fallon JT, Waters D, Chen C. Remodeling of small intramyocardial coronary arteries distal to a severe epicardial coronary artery stenosis. Arterioscler Thromb Vasc Biol. 2002 Dec 01; 22(12):2059-65.

Hsia J, Alderman EL, Verter JI, Rogers WJ, Thompson P, Howard BV, Cobb FR, Ouyang P, Tardif JC, Higginson L, Bittner V, Barofsky I, Steffes M, Gordon DJ, Proschan M, Younes N, Waters D. Women's angiographic vitamin and estrogen trial: design and methods. Control Clin Trials. 2002 Dec; 23(6):708-27.

Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, Ouyang P, Thompson P, Tardif JC, Higginson L, Bittner V, Steffes M, Gordon DJ, Proschan M, Younes N, Verter JI. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002 Nov 20; 288(19):2432-40.

Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, Ezekowitz M, Chaitman BR, Leslie SJ, Stern T. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation. 2002 Sep 24; 106(13):1690-5.

Ansell BJ, Waters DD. Reassessment of National Cholesterol Education Program Adult Treatment Panel-III guidelines: one year later. Am J Cardiol. 2002 Sep 01; 90(5):524-5.

Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002 Jul 03; 288(1):49-57.

Gemayel C, Waters D. Mechanical or metabolic treatment for coronary disease: synergistic, not antagonistic, approaches. Cardiol Rev. 2002 May-Jun; 10(3):182-7.

Hsue PY, Salinas CL, Bolger AF, Benowitz NL, Waters DD. Acute aortic dissection related to crack cocaine. Circulation. 2002 Apr 02; 105(13):1592-5.

Thompson PD, Moyna NM, White CM, Weber KM, Giri S, Waters DD. The effects of hydroxy-methyl-glutaryl co-enzyme A reductase inhibitors on platelet thrombus formation. Atherosclerosis. 2002 Apr; 161(2):301-6.

Waters DD. Estrogen therapy for unstable angina: another bump for the bandwagon. J Am Coll Cardiol. 2002 Jan 16; 39(2):238-40.

Giri S, Shaw LJ, Murthy DR, Travin MI, Miller DD, Hachamovitch R, Borges-Neto S, Berman DS, Waters DD, Heller GV. Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. Circulation. 2002 Jan 01; 105(1):32-40.

Waters D, Schwartz GG, Olsson AG. The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins? Curr Control Trials Cardiovasc Med. 2001; 2(3):111-114.

  Select data provided by UCSF Profiles, powered by CTSI at UCSF. Learn more about the data source.